Bookmark and Share
oxiracetam (CID 4626) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(3)
 
 
Inactive(303)
 
 
Inconclusive(6)
 
 
Unspecified(25)
 
 
Top Targets:
NR LBD ER(8)
 
 
7tm 4(8)
 
 
NR LBD AR(7)
 
 
NR LBD TR(5)
 
 
Pyr redox dim(5)
 
 
BioAssay Types:
Confirmatory(210)
 
 
 
 
 
Literature(94)
 
 
 
 
Summary(16)
 
 
 
Screening(15)
 
 
BioActivity Types:
Potency(222)
 
 
 
 
 
EC50(2)
 
 
IC50(1)
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 250    Data Row: 337   Total Pages: 17   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID50106803]
Potency 2.8184qHTS for differential inhibitors of proliferation of Plasmodium falciparum line HB3 [AID1886, Type: confirmatory]
View
2
[SID103213022]
EC50 5.96NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay [AID449703, Type: Literature]
View
3
[SID103213022]
EC50 6.22NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay [AID449704, Type: Literature]
View
4
[SID103213022]
CC50 57.48NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) [AID449705, Type: Literature]
View
5
[SID103213022]
NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested. [AID449706, Type: Literature]
View
6
[SID103213022]
Amnesia-reversal activity in ECS-induced amnesia model of mice at 1 mg/kg i.p. [AID125741, Type: Literature]
View
7
[SID103213022]
Amnesia-reversal activity in ECS-induced amnesia model of mice at 10 mg/kg i.p. [AID125742, Type: Literature]
View
8
[SID103213022]
Amnesia-reversal activity (AA) evaluated in ECS-induced amnesia model of mice at a dose of 100 mg/kg [AID125743, Type: Literature]
View
9
[SID103213022]
Amnesia-reversal activity in scopolamine-induced amnesia model of mice at 1 mg/kg i.p. [AID125744, Type: Literature]
View
10
[SID103213022]
Percent reversal of scopolamine-induced amnesia rat following 1.0 mg/kg i.p. [AID191743, Type: Literature]
View
11
[SID103213022]
Percent reversal of scopolamine-induced amnesia rat following 10 mg/kg i.p. [AID191745, Type: Literature]
View
12
[SID103213022]
Percent reversal of scopolamine-induced amnesia rat at 10 mg/kg po [AID191746, Type: Literature]
View
13
[SID103213022]
Percent reversal of scopolamine-induced amnesia rat at 30 mg/kg po [AID191747, Type: Literature]
View
14
[SID103213022]
Total clearance in human [AID444051, Type: Literature]
View
15
[SID103213022]
Hepatic clearance in human [AID444052, Type: Literature]
View
16
[SID103213022]
Renal clearance in human [AID444053, Type: Literature]
View
17
[SID103213022]
Oral bioavailability in human [AID444054, Type: Literature]
View
18
[SID103213022]
Fraction absorbed in human [AID444055, Type: Literature]
View
19
[SID103213022]
Fraction escaping gut-wall elimination in human [AID444056, Type: Literature]
View
20
[SID103213022]
Fraction escaping hepatic elimination in human [AID444057, Type: Literature]
View